Study of AC0058TA in Healthy Male and Female Subjects
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
AC0058TA is a small molecule compound that potently, selectively and irreversibly inhibits
Bruton's tyrosine kinase (BTK) phosphorylation and downstream signals, resulting in
inhibition of inflammatory cytokine production in monocytes and inhibition of lymphocyte
activation (predominantly B-cell activation) in the preclinical studies. The nonclinical
program has demonstrated that AC0058TA has the potential to interfere with signaling
functions mediated by tyrosine kinases and may be useful for controlling excessive or
aberrant T- and B-cell activation in autoimmune diseases.
As an investigational targeted therapy for RA and SLE, AC0058TA is expected to address the
unmet need of this patient population, for whom there are currently no effected therapies and
there is a great unmet medical need, AC0058TA may inhibit the key pathway which involves the
disease process.